CME online

in association with the 8th Heart in Diabetes (HiD)

Comorbidities of Diabetes and/or CardioRenal Metabolism− Diagnosis & Management

This is a CME Symposium Supported by an Educational Grant from AstraZeneca
Provided By:

Administrated by::
This CME online educational activity is approved for a maximum of 2.0 AMA PRA Category 1 Credits ™.
Accreditation period: August 1, 2024 – August 1, 2025

To get started:

Login / Register
CME information
View Agenda
Course presentation

To Receive a Certificate for This CME Activity:  

View the presentations in this CME activity and complete the evaluation. Your certificate will be mailed to you upon satisfactory completion of these documents.

Comorbidities of Diabetes and/or CardioRenal Metabolism− Diagnosis & Management
Agenda

Introduction & Pre-CME Questions

Comorbidities in Diabetes and/or CardioRenal Metabolism
Mark E. Cooper, AO, MBBS,PhD

Management of CKD – Concomitant vs Sequential
Anjay Rastogi, MD, PhD

The Contemporary Approach to the Management of HF
Akshay S. Desai, MD, MPH

Panel Discussion and Q&A: Proper Differential Diagnosis- Impact on Management
Moderator: Yehuda Handelsman, MD
Panel: Mark E. Cooper, AO, MBBS, PhD • Anjay Rastogi, MD, PhD • Akshay S. Desai, MD, MPH
Moderator: Yehuda Handelsman, MD

Faculty

Yehuda Handelsman, MD, FACC, FAHA, FACP, FNLA, FASPC, FAHA, MACE

Medical Director & Principal Investigator
The Metabolic Institute of America
Chair Scientific Advisory board, DCMi– Diabetes
CardioRenal & Metabolism Institute
Chair & Program Director, Heart in Diabetes
Tarzana, California

Mark E. Cooper, AO, MBBS, PhD, Chair FRACP

Head, Department of Diabetes
Central Clinical School
Monash University
Senior Endocrinologist, Alfred Health Clinic
Melbourne, Australia


Anjay Rastogi, MD, PhD

Professor and Clinical Chief
Director of UCLA CORE Kidney Health Program
Division of Nephrology, Department of Medicine
David Geffen School of Medicine, UCLA
Los Angeles, CA

Akshay S. Desai, MD, MPH
FRSE, FMedSci, OBE

Associate Professor of Medicine Harvard Medical School
Director of the Cardiomyopathy and
Heart Failure Program
Center for Advanced Heart Disease,
Cardiovascular Division
Brigham and Women’s Hospital
Boston, Massachusetts

Program Description

Comorbidities of diabetes &/or cardiorenal metabolism are CVD, cardiomyopathy, heart failure (HF), chronic kidney disease (CKD) as well as retinopathy and neuropathy. Several of these conditions, specifically cardiomyopathy and neuropathy do not have effective treatments. It is often ignored that these conditions, specifically cardiomyopathy and neuropathy, may have different etiologies which unlike DM related may have available treatments. Specifically, amyloidosis may cause deposition of amyloid fibrils in nerve, cardiac, renal, and other tissues. Transthyretin amyloidosis (ATTR), a genetic form of amyloidosis, is often fatal, however recently new medications treating these diseases were approved. This highlights that differential diagnosis of cardiomyopathy and polyneuropathy is essential to properly manage these conditions as currently, unlike DM related conditions, there are treatment options for ATTR based conditions. The symposium will explore strategies for correctly diagnosing and managing patients with treatable forms of these comorbidities.




Learning Objectives

Upon completion of this CME symposium, participants should be able to:

  • Describe the epidemiology and pathophysiology of diabetes comorbidities, including polyneuropathy and cardiomyopathy and the need to differentiate them from other etiologies like amyloidosis
  • Review evidence supporting use of SGLT2 inhibitors alone and in combination with RAS inhibitors and/or MRAs for the treatment of CKD
  • Compare and contrast guideline-directed medical therapy for different forms of HF based on LVEF
  • Develop strategies for the differential diagnosis of obesity and diabetes complications, such as hyperglycemia, amyloidosis, and hypertension in order to recognize treatable conditions

    • Target Audience

    This educational initiative is designed for cardiologists, nephrologists, endocrinologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of CKD and HF and prevention of morbidity and mortality.

    CME Statement

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PESI, Inc. is accredited by the ACCME to provide continuing medical education for physicians. Administrated by the Metabolic Institute of America.

    PESI, Inc. designated this live educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s).

    For information please contact: [email protected] or 818 342 1889